Comparable drug levels and immunogenicity in patients with axial spondyloarthritis treated with adalimumab originator and biosimilar: A retrospective study from two centers of China.

Authors :: Fu ZC
Cheng XG
Zhang GW
Shi RG
Zhang LJ
Sun HT
Huang JX
Source :: International journal of rheumatic diseases [Int J Rheum Dis] 2024 May; Vol. 27 (5), pp. e15190.
Publication Year :: 2024

Subjects :: Humans
Retrospective Studies
China epidemiology
Female
Male
Treatment Outcome
Adult
Antirheumatic Agents therapeutic use
Middle Aged
Tumor Necrosis Factor Inhibitors therapeutic use
Tumor Necrosis Factor Inhibitors adverse effects
Adalimumab therapeutic use
Biosimilar Pharmaceuticals therapeutic use
Biosimilar Pharmaceuticals adverse effects
Axial Spondyloarthritis diagnosis
Axial Spondyloarthritis immunology
Axial Spondyloarthritis drug therapy

Full Text Access

Tools